A former U.S. budget official says last year's BioShield legislation was intended to promote drug availability to counter biological and other terror threats but instead encourages higher drug prices. J.T. Young, writing in The Washington Times, says drugmakers are seeking patent enlargement under the guise of responding to bioterrorism and the result may be more expensive drugs and a disincentive to adopt cost-saving health information technology.

Related Summaries